Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
/in HIV/AIDS, International Publications /von 2007-10-17 / Clin. Vaccine Immunol. 2008 Feb;15(2):284-92Breast cancer vaccines: promise for the future or pipe dream?
/in Breast Cancer, International Publications /von 2007-10-15 / Cancer 2007 Oct;110(8):1677-86Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-9Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein
/in Chronic Virus Hepatitis, International Publications /von 2007-10-09 / Mol. Ther. 2008 Jan;16(1):210-7Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study
/in International Publications, NSCLC /von 2007-10-06 / BMC Cancer 2007 Oct;7:189Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease Virus /von 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
/in Hypernephroma, International Publications /von 2007-10-03 / Clin. Immunol. 2007 Dec;125(3):257-67Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses
/in International Publications, Micronutrients /von 2007-10-01 / Br. J. Nutr. 2007 Oct;98 Suppl 1:S29-35Dendritic cell immunotherapy for stage IV melanoma
/in International Publications, Malignant Melanoma /von 2007-10-01 / Melanoma Res. 2007 Oct;17(5):316-22
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution